Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP16 in STEMI (SPIRIT)
NCT04225533Phase 2Completed
- Sponsor
- Serpin Pharma
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of SP16 in myocardial infarction (MI), sponsored by Serpin Pharma. Started Feb 2020; status: completed.
02
Drugs
SP16
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04225533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225533.